ProBDNF, a precursor of brain-derived neurotrophic factor (BDNF), is anterogradely transported and released from nerve terminals, but the mechanism underlying this process remains unclear. In this study, we report that proBDNF forms a complex with Huntingtin associated protein-1 (HAP1) and sortilin, which plays an important role in proBDNF intracellular trafficking and stabilization. The interaction of proBDNF with both HAP1A and sortilin in co-transfected HEK293 cells is confirmed by both fluorescence resonance energy transfer (FRET) and coimmunoprecipitation (Co-IP). The frequent colocalization (>90%) of endogenous HAP1, sortilin and proBDNF is also found in cultured cortical neurons. Mapping studies using GSTpull down and competition assays has defined the interacting region of HAP1 with proBDNF within amino acids (aa) 371-445 and the binding sequences of proBDNF to HAP1 between aa 65-90. Fluorescence recovery after photobleaching (FRAP) confirms the defective movement of proBDNF-containing vesicles in neurites of HAP1 -/-neurons, which can be partially restored by re-introducing HAP1 cDNA into the neurons. However, the effect is significantly increased by simultaneously reintroducing both HAP1 and sortilin. ProBDNF and HAP1 are highly co-localized with organelle markers for the Golgi network, microtubules, molecular motor or endosomes in normal neurons, but this co-localization is reduced in HAP1 -/-neurons. Co-IP and Western blot showed that sortilin stabilizes the proBDNF/HAP1 complex in co-transfected HEK293 cells, helping to prevent proBDNF degradation. Furthermore, the complex facilitates the furin cleavage to release mature BDNF.
ProBDNF, a precursor of brain-derived neurotrophic factor (BDNF), is anterogradely transported and released from nerve terminals, but the mechanism underlying this process remains unclear. In this study, we report that proBDNF forms a complex with Huntingtin associated protein-1 (HAP1) and sortilin, which plays an important role in proBDNF intracellular trafficking and stabilization. The interaction of proBDNF with both HAP1A and sortilin in co-transfected HEK293 cells is confirmed by both fluorescence resonance energy transfer (FRET) and coimmunoprecipitation (Co-IP). The frequent colocalization (>90%) of endogenous HAP1, sortilin and proBDNF is also found in cultured cortical neurons. Mapping studies using GSTpull down and competition assays has defined the interacting region of HAP1 with proBDNF within amino acids (aa) 371-445 and the binding sequences of proBDNF to HAP1 between aa 65-90. Fluorescence recovery after photobleaching (FRAP) confirms the defective movement of proBDNF-containing vesicles in neurites of HAP1 -/-neurons, which can be partially restored by re-introducing HAP1 cDNA into the neurons. However, the effect is significantly increased by simultaneously reintroducing both HAP1 and sortilin. ProBDNF and HAP1 are highly co-localized with organelle markers for the Golgi network, microtubules, molecular motor or endosomes in normal neurons, but this co-localization is reduced in HAP1 -/-neurons. Co-IP and Western blot showed that sortilin stabilizes the proBDNF/HAP1 complex in co-transfected HEK293 cells, helping to prevent proBDNF degradation. Furthermore, the complex facilitates the furin cleavage to release mature BDNF.
BDNF is a member of the neurotrophin family that plays a role in neuronal development and plasticity (1) (2) (3) (4) (5) (6) . Like all neurotrophins, BDNF is synthesized as a precursor (proBDNF) encompassing two domains, the prodomain and the BDNF domain (7) . The proBDNF is cleaved by prohormone convertases such as furin and plasminogen/plasmin (8) (9) (10) to release the mature form (11) . The newly synthesized proBDNF is transported anterogradely in neurons and released from the nerve terminal in an activity-dependent manner (9, (12) (13) (14) (15) (16) . The released BDNF regulates neuronal survival, differentiation, dendritic morphology and synaptic plasticity, which are important for memory and learning (14, (17) (18) (19) . The neurotrophic receptor-mediated retrograde transport of BDNF is well recognized (20) (21) (22) , but the mechanism of its anterograde transport remains unclear. A recent study has suggested that Huntingtin protein (Htt), the p150 Glued component of the dynactin complex (p150 Glued ) and microtubules are involved in the anterograde transport of BDNF (23) . Kinesin (24) (25) (26) and dynein (24, 27, 28) motor proteins move along microtubules and participate in axonal anterograde and retrograde transport, respectively. It has been found that dynactin binding of dynein mediates vesicle ER-Golgi transport (29) . Huntingtin associated protein 1 (HAP1) interacts with p150 glued subunit of dynactin (30) and regulates trafficking and membrane targeting of vesicles. HAP1 interacts with a number of proteins including the gamma-aminobutyric acid receptor (GABA A R) (31, 32) and neurotrophic factor receptors (33, 34) . HAP1 and sortilin co-exist in stigmoid-like bodies, a type of protein aggregation structure of unknown function found in neurons of healthy animals, in vivo (35) . More emerging evidence suggests that both sortilin and carboxypeptidase E play significant roles in posttranslational Golgi sorting of BDNF to the regulated secretory pathway (36, 37) .
Sortilin is highly expressed in neuronal cells (38) and mostly distributed in the Trans-Golgi Network (TGN) (39) (40) (41) (42) . Its extracellular domain (ECD) contains a homologous sequence to yeast vacuolar protein sorting 10 protein (VPS10p), which acts as a multi-ligand receptor, and binds to many proteins including proneurotrophins and p75 neurotrophin receptor (p75NTR) (43) . The short intracellular domain (ICD) is involved in Golgiendosome sorting (42, 44) .
The prodomain of BDNF plays an important role in the secretion and anterograde transport of proBDNF (36) . For example, methionine substitution at codon 66 reduces BDNF transport and activitydependent secretion (3) . This polymorphism also causes reduction of hippocampal volume, impairment of episodic learning (45, 46) and a number of neurological disorders (47) (48) (49) . However the mechanism underlying the defect in BDNF trafficking remains unknown. PolyQ huntingtin (htt) reduces BDNF mRNA expression and axonal transport of BDNF (50) (51) (52) by disrupting the interaction with HAP1 and p150 glued (23) and the phosphorylation of S421 in polyQ htt rescues the defect in BDNF transport (53) . In a previous study, we have demonstrated that HAP1 may regulate axonal transport of proBDNF by interacting with the prodomain of BDNF (54) . In the present study, we have further characterized the role of HAP1 and sortilin in sorting and trafficking of proBDNF and found that HAP1 and sortilin form a complex with proBDNF, preventing proBDNF degradation and modulating its targeting to endosomes, microtubules and neurites.
EXPERIMENTAL PROCEDURES
Animals-All procedures involving animals were approved by the Animal Welfare Committee of Flinders University and undertaken according to the guidelines of the National Health and Medical Research Council of Australia. The use of genetically modified animals was approved by the Biosafety Committee of Flinders University. HAP1 knockout mice were generated as described previously (55) . All animals were kept under standardized barrier breeding conditions (12-h light/12-h dark cycle) with free access to water and food. PCR genotyping of HAP1 knockout mice was carried out using primers 5'-TTTTGGAGGTCTGGTCTCGCTCTG-3'/ 5'-CGTCTTCCATCTTAGTGCGTTCAC -3'for wild type and TTTTGGAGGTCTGGTCTCGCTCTG-3' / 5'-CTTCATGTGGATGCTAGGGATCC-3'for knockout animals. Plasmid constructs-The constructs of rat mature BDNF, proBDNF and prodomain-CFP or YFP were made by PCR with primers (mature primer set:
5'-GCGAATTCATGCACTCCGACCCT-3'/5'-ATGGCGACCGGTGGATCCCT-3' , proBDNF primer set: 5'-GCGAATTCCACCAGGTG-3'/5'-ATGGCGACCGGTGGATCCCT-3' and the prodomain primer set: 5'-GCGAATTCCACCAGGTG-3'/5'-ATGGATCCCGCCGAACCCT-3'), amplifying EcoR1 and BamH1 fragment from proBDNF-EGFP (a gift from Dr. Masami Kojima, Research Institute for Cell Engineering, National Institute of Advanced Industrial Science and Technology, Ikeda, Osaka, Japan) and cloning into pECFP-N1 or pEYFP-N1 (Clontech). The pcDNA3.1 constructs of prodomain, proBDNF and mature BDNF were generated by PCR, amplifying the respective region with primers (prodomain primer set:
5 '-TGCAAGCTTGCCACCATGACCATCCTTTTC  CTTACT  -3'/  5'-TGCCTCGAGCGTGGCGCCGAACCCTCATA  G-3';  proBDNF  primer  set:  5'-TGCAAGCTTGCCACCATGACCATCCTTTTC  CTTACT  -3'/  5'-TGCCTCGAGCTCTTCCCCTTTTAATGGTC -3';  BDNF  primer  set  5'-TGCAAGCTTGCCACCATGCACTCCGACCC  YGCCCGC  -3'/5'-TGCCTCGAGCTCTTCCCCTTTTAATGGTC -3' ) from AAproBDNF-EGFP (a furin-resistant construct with amino acids 129 and 130, RR to AA mutations from Dr. Masami Kojima). HAP1-CFP-N1 and HAP1-YFP-N1 were derived by cloning a PCR product generated from PRK-HAP1 (from Dr. Li) using appropriate primers (5'-TAGCTAGCATGCGCCCGAAGGAC-3' and 5'-GAGGTACCAGGGTTGATGATCG GTAGC-3') in the NheI and KpnI sites of pECFP-N1and pEYFP-N1 (Clontech). The integrity of all cloned constructs was determined by DNA sequence analysis in both directions. p75CFP-YFP was a gift from Dr. E. Coulson (The University of Queensland, Australia). Cell culture-Human embryonic kidney 293 cells (HEK293) and rat pheochromocytoma cells (PC12) were obtained from the American Type Culture Collection (ATCC; Rockville, MD) and maintained in DMEM medium (Invitrogen) supplemented with 10% fetal bovine serum (FBS) and 2mM glutamine. Mouse cortical neurons were prepared from the brains of wild-type or HAP1 -/-neonates as described (56) -/-mice using a RNAeasy Mini kit (Qiagen, CA). The RNA concentration and purity were determined using a NanoDrop® ND-1000 UV-Vis spectrophotometer (Thermo Fisher Scientific). The first-strand cDNA was synthesized from 0.3µg total RNA using QIAGEN QuantiTect Rev Transcription Kit. The SYBR Green real-time PCR was performed using a Rotorgene 3000 (Corbett Research, Australia) in triplicates using Qiagen PCR kit with specific primers for mouse proBDNF (forward primer 5'-ATGACCATCCTTTTCCTTACT-3' and reverse primer 5'-GCGCCGAACCCTCATAGAC-3') and normalized against the housekeeping gene GAPDH (forward primer 5'-AACATCATCCCTGCATCCAC-3' and reverse primer 5'-TTGAAGTCRCAGGAGACAAC-3'). Real-time quantitative PCR analysis was then performed using Q-Gene software (57) with the amplification efficiency applied to the relative concentration analyses of both the genes of interest and the housekeeping gene (GAPDH). Gene of interest expression data was normalized by dividing the corresponding levels of GAPDH for each sample. Co-immunoprecipitation (Co-IP) and GSTpulldown/competition assay-HEK293 cells cotransfected with HAP1A-CFP, sortilinpcDNA3.1/Myc (a gift from Dr. C. Morales) and/or proBDNF-pcDNA3.1/Myc , (RRH furin cleavage site mutant) were prepared in radio immunoprecipitation assay (RIPA) buffer containing 2 mM phenylmethanesulfonylfluoride (PMSF) and protease inhibitors (Roche) for cell lysates. The protein concentration of the lysates was determined using BCA protein assay Kit (Thermo Scientific, Rockford, USA). All lysates were stored at -80ºC until use. To reduce the nonspecific binding to protein G beads, the cell lysate was precleared with protein G beads according to the manufacturer's instructions (Sigma). The precleared lysates (250µg) of HEK293 cells were then incubated at 4ºC for 1 hr with protein G beadimmobilized anti-sortilin (rabbit, ab16640, Abcam) or anti-HAP1 (rabbit, a gift from Dr. M. DiFiglia，Harvard Medical School，MA) or antiproBDNF (sheep) or anti-GFP (rabbit, ab290, Abcam). The beads were washed five times and boiled in loading buffer for Western blot using anti-HAP1, anti-sortilin or anti-proBDNF. For negative control, rabbit or sheep IgG was used in the same way for validation.
GST-HAP1 constructs (HAP1 1-350, HAP1 280-445, HAP1 371-599, HAP1 328-599, HAP1 240-599, HAP1 215-599, HAP1 153-599) were gifts from Dr Josef Kittler (Department of Neuroscience, Physiology, and Pharmacology, University College London, Gower Street, London, WC1E 6BT, UK). GST-HAP1 fusion proteins were produced in E.coli BL21 (Invitrogen) and purified with glutathione-agarose beads (Sigma). The proBDNF lysates were incubated with GST-HAP1 fusion protein (2 µg) coupled to 40 µl of glutathione agarose beads at 4ºC for 2 hours. After washing with RIPA buffer five times, proteins bound to the beads were subjected to Western blot analysis with rabbit anti-GFP (Abcam) or mouse anti-Myc antibodies (Invitrogen).
For the competition assay, the proBDNF lysates were incubated with proBDNF peptides (proBDNF 44-60 ESVNGPKAGSRGLTSLA, proBDNF 55-74 GLTSLADTFEHVIEELLDED, proBDNF 65-80 HVIEELLDEDQKVRPN, proBDNF 75-90 KVRPNEENNKDADLY and proBDNF 85-100 KDADLYTSRVMLSSQV) (Peptides international, USA) and one nonspecific prostate-specific membrane antigen peptide (PSMA, NH-PQSGAAVVHEIVRSFG-OH, accession No. NP001014986) (Auspep Australia), respectively at 4ºC for 1 hour prior to addition of GST-HAP1 fusion proteins. Then, GST-HAP1 fusion protein (2 µg) coupled to 40 µl of glutathione agarose beads was supplemented for a further 2 hours of incubation.
The beads were washed five times with RIPA buffer and subjected to Western blot with rabbit anti-GFP antibody (Abcam). Western blot-Lysates of transfected HEK293 cells were prepared using RIPA buffer supplemented with 2 mM PMSF and protease inhibitors (Roche). The protein concentration of the lysates was determined using BCA protein assay Kit (Thermo Scientific, Rockford, USA). Lysate proteins (50 µg) were analysed by 10% SDS-PAGE and transferred to nitrocellulose membrane (Hybond ECL, GE Heallthcare). Corresponding primary antibodies (1:1000) were incubated with blots at 4ºC overnight. Horseradish peroxidase-conjugated (HRP) secondary antibodies (1:2000) were used for detection. β-Actin was used as a loading control. Imaging was performed using ECL (GE). ImageJ (NIH) was used for quantitative analysis. Immunocytochemistry-Antibodies to proBDNF were generated by immunization of sheep with synthetic peptide, corresponding to the 14 amino acids of the pre-region sequence of proBDNF, which were conjugated to hemocyanin (KLH) (58, 59) . ProBDNF monoclonal antibody (PB17-2A) was prepared by immunization of BALB/c mice with the same peptide. The antibody was thoroughly characterized for specificity and binding capacity by Western blot and immunohistochemistry in parallel with sheep proBDNF antibody. This antibody only recognizes proBDNF but does not stain for mature BDNF. CD71 (endosome marker, goat, sc-7087), Secretogranin II (SgII, rabbit), HAP1 polyclonal (rabbit, sc-30126) and monoclonal (mouse, sc166245) antibodies were purchased from Santa Cruz (CA, USA). Tau (ab80579), MAP2 (Neuronal marker, ab32454) and GM130 (cisGolgi marker, ab1299) antibodies were purchased from Abcam (Cambridge, USA). Monoclonal p150 Glued antibody (mouse 612709) was purchased from BD Biosciences (CA, USA). Sortilin antibody (rabbit, OSC-203) was purchased from Osenses (Australia). All fluorescent conjugated secondary antibodies were purchased from Sigma. For single and multiple labelling of mouse cortical neurons or transfected cells, appropriate combinations of primary and secondary antibodies were used. Images were acquired and analysed by BX50 fluorescence microscope (Olympus) and Leica SP5 confocal microscope. FRAP in live cells-Mouse cortical neurons were cotransfected with proBDNF-YFP alone or proBDNF-YFP/HAP1A or proBDNF-YFP/HAP1A/sortilin for 36 hours. The culture medium was then replaced with CO 2 -independent medium. Cells in FluoroDishes were imaged using Leica SP5 Spectral Confocal Microscope equipped with a 37 ºC heating device, according to the manufacturer's recommendation. Briefly, the fluorescence of YFP was assessed before and after photobleaching in a time series. Two scans were set before bleaching. To bleach YFP, the laser was set to 100% for both 496 nm and 514 nm and six bleaches were taken. A total of 30 scans were performed at 3 second intervals after bleaching. For background correction and fluorescence loss, regions of interest (ROI) were also selected from unbleached cell regions and outside of the cells. For each wild type or HAP1 -/-genotype, 6 neurons were examined and the fluorescent data was averaged at each time point. FRET Acceptor Bleaching-PC12 cells were transfected with proBDNF-CFP and HAP1A-YFP plasmids or control plasmids as shown in Table 1 . FRET was performed using Leica SP5 Spectral Confocal Microscope according to the manufacturer's recommendation (Leica). Briefly, acceptor bleaching was used to compare the donor fluorescence intensity in the same sample before and after photo bleaching the acceptor. If there is FRET, the intensity of the donor fluorescence increases after photo-bleaching the acceptor. The efficiency of FRET can be determined as: positive control. A pair of proteins such as proBDNF-CFP and pEYFP which show no interaction was used as a negative control. In addition, the signal of proBDNF-CFP from the surrounding cells in an adjacent region which expressed proBDNF-CFP alone was used as background. Each value of FRET eff from the tested samples including positive, negative and background controls were determined according to a mean of 6 individual tests from different viewing fields. The results were summarized from 3 different experiments. Statistical Analysis-All statistical analyses were performed with SPSS software (version 18.0). Data were expressed as means ± SEM and p<0.05 was considered significant. Variables between groups were determined by independent or paired t-test.
RESULTS

Prodomain of BDNF interacts with HAP1.
To strengthen the finding that HAP1 directly associates with proBDNF, we performed Co-IP ( Given that the background can cause false FRET signals, controls were used for quantifying the FRET efficiency (FRET eff ) in transfected PC12 cells. The transfection using proBDNF-CFP / pEYFP plasmids for negative control resulted in a 2% FRET eff , which was similar to the background. The positive control, p75CFP-YFP fusion protein, showed an elevated FRET eff up to 10% and a five-fold increase compared with background and negative controls. Therefore, the 2% of FRET eff was used as a cut-off in this study. The FRET eff from proBDNF-CFP/HAP1A-YFP was 18% when the measuring area was focused on the vesicle, suggesting a close proximity between proBDNF and HAP1A. Furthermore, a higher FRET eff was seen from prodomain-CFP / HAP1A-YFP, evident by a 23% of FRET eff directly from the targeted vesicle, suggesting that the prodomain is closer to HAP1A. In contrast, the FRET eff between the mature BDNF-CFP and HAP1A-YFP was less than 2%, indicating no direct interaction between this pair. Taken together, these data confirm our previous findings and indicate that HAP1A is a component of the proBDNF complex.
HAP1A is specifically colocalized with proBDNF-containing vesicles and lack of HAP1 impairs neuritic proBDNF distribution. To investigate whether the interaction between HAP1 and proBDNF has any physiological significance, we examined the distribution of HAP1 and proBDNF in live PC12 cells co-transfected with HAP1A-YFP and proBDNF-CFP or prodomain-CFP using the Nikon Biostation. As shown in merged panels (yellow), HAP1A (green) was highly co-localized with proBDNF (red) (90%) and the prodomain of BDNF (red) (87%) (Fig.  2A) . To rule out the possibility of non-specific binding of protein due to overexpression, we stained endogenous proBDNF and HAP1 in cultured and fixed mouse cortical neurons with specific antibodies to proBDNF. It was shown that proBDNF was highly colocalized with HAP1 in both soma and neurites of wild type neurons (91%) whereas proBDNF was only present in cell soma or proximal neurites of HAP1 -/-neurons compared to MAP2 staining ( Fig. 2A) . However, the stigmoid-like bodies found in transfected PC12 cells were not seen in cortical neurons. It is possible that the overexpression of HAP1 recruited proBDNF in large aggregates. To quantitatively analyze the transport of neuritic proBDNF, we measured the length of neurites fluorescently stained by anti-proBDNF and anti-MAP2 (the total length of neurites). The ratio of proBDNF and MAP2 was plotted in Fig.  2A at the bottom left. The ratio is significantly lower in HAP1 -/-neurons than in WT neurons. However, we found no significant change in the neuritic distribution of secretogranin II-containing vesicles between HAP1 -/-and WT neurons (Fig.  2B ). To see whether lower level of proBDNF in neurites was due to down-regulation of proBDNF mRNA transcription by HAP1 knockout, we examined if proBDNF mRNA is normally expressed in HAP1 -/-neurons. The proBDNF mRNA levels in the cortex and dorsal root ganglia (DRG) of wt and HAP1 -/-mice were analysed by a quantitative real time RT-PCR. The data showed no significant difference in BDNF mRNA expression between wt and HAP1 -/-mice (Fig. 2C  top) . Interestingly, proBDNF protein level of the cortex was significantly lower in HAP1 -/-mice than WT mice (Fig. 2C bottom) . However, the decreased level of proBDNF alone does not fully explain the observation by immunohistochemistry that proBDNF is lacking in the neurites. We postulate that a mechanism other than protein expression may result in deficiencies in proBDNF transport in the HAP1 -/-neurons. Taken together with the findings that mRNA levels were not changed, the data suggest that proBDNF protein may be less stable in HAP -/-cortex. Mapping proBDNF and HAP1 binding sites. To identify the proBDNF binding sites in HAP1, we performed a GST-HAP1 pull-down assay. Seven GST-HAP1 constructs (HAP1 1-350, HAP1 280-445, HAP1 371-599, HAP1 328-599, HAP1 240-599, HAP1 215-599, HAP1 153-599) (31) were incubated with proBDNF-containing cell lysates. Except HAP1 1-350, all other constructs pulled down proBDNF (Fig. 3A) . Based on overlapping, the region of HAP1 between aa 371-445 contained proBDNF binding sites. The flanking region structure may be involved in the binding as well because lack of these regions decreased the interaction (Fig. 3A) . To determine the binding region of proBDNF to HAP1, we added proBDNF peptides as competitors in the pulldown assay. Interestingly, all five proBDNF peptides except the negative control of PSMA showed inhibitory effects, but the greatest inhibition (>80%) resulted from two peptides, proBDNF 65-80 and proBDNF 75-90 (Fig. 3B) . These results suggest that the region between aa 65-90 of the prodomain has a key structure for HAP1 binding.
Deficient proBDNF trafficking in HAP1
-/-neurons. To confirm our immunostaining results on co-localization and transport of proBDNF in neurons, we examined proBDNF trafficking in WT and HAP1 -/-neurons using FRAP. We transiently transfected cultured WT and HAP1 -/-cortical neurons with proBDNF-YFP and measured the movement of proBDNF-YFP in the neurites of mouse cortical neurons. After bleaching proBDNF-YFP, the maximum recovery of its fluorescence was 87% in WT neurons and 78% in HAP1 -/-neurons (Fig. 4A) . When measuring the recovery velocity (time for 50% of fluorescent recovery), HAP1 -/-neurons took longer (24s) than wt neurons (15s), showing that the difference was significant (p<0.05) (Fig. 4B) . To see whether the re-introduction of HAP1 to HAP -/-neurons could rescue the phenotype, we cotransfected HAP -/-neurons with both HAP1A-CFP and proBDNF-YFP plasmids. We found that the time for 50% of fluorescent recovery was 5s shorter in dual co-transfected HAP -/-neurons (Fig.  4B) . Interestingly, the recovery was further improved by cotransfection in conjunction with sortilin cDNA plasmids, showing that the time for 50% of fluorescent recovery was similar to that in WT (p>0.05) (Fig. 4B) . Therefore, it was evident that the exogenous expression of HAP1A in conjunction with sortilin was able to rescue the defect in proBDNF trafficking in HAP1 -/-neurons. The proBDNF/HAP1 complex is present in different organelles. To investigate how proBDNF is intracellularly transported, we analyzed the distribution and association of proBDNF/HAP1 complex with Golgi network, microtubules (MTs), endosomes and p150
Glued structures in cortical neurons. We found that both HAP1 and proBDNF were distributed in Golgi apparatus and that a number of yellow spots from overlap between proBDNF and HAP1 were observed on one side of the Golgi apparatus in WT neurons (Fig.   5A , top panel), suggesting that HAP1 may be involved in sorting proBDNF to the TGN and secretory pathway. In contrast, most proBDNF gathered around cis-Golgi-apparatus in HAP1 -/-neurons (Fig. 5A, bottom panel) . More than 90% of HAP1 or proBDNF was also co-localized with endosomal marker CD71 in WT neurons (Fig. 5B , top panel), indicating that endosomes may participate in sorting of the HAP1/proBDNF complex via TGN or may be involved in the transport of proBDNF/HAP1 complex. However, a decreased (65%) co-localization of proBDNF with endosomal marker CD71 was found in HAP1 -/-neurons ( Fig. 5B bottom panel) , compared with wt neurons. Our results showed that the proBDNF/HAP1 complex was localized with microtubule marker Tau in both axons and soma (Fig. 5C ). In addition, 96% of proBDNF was co-localized with molecular motor protein p150
Glued in WT neurons, whereas only 71% was observed in HAP1 -/-neurons (Fig. 5D ), suggesting that HAP1 contributes to targeting proBDNF to molecular motor proteins.
proBDNF, HAP1, and sortilin form a complex. Our results revealed that proBDNF was highly colocalized with HAP1 at trans-Golgi network (TGN). ProBDNF is known to interact with HAP1 and sortilin (36) . Therefore, we postulated that proBDNF, HAP1 and sortilin might form a complex which could be involved in sorting of proBDNF at TGN. To test this hypothesis, we firstly investigated whether HAP1 associated with sortilin, because 90% sortilin is found in transGolgi network (39, 42) . Sortilin is also reported to co-localize with HAP1 in stigmoid bodies, a type of protein aggregation structure of unknown function found in neurons of healthy animals (35) . We found that approximately 91% of endogenous HAP1 and sortilin were co-localized in cortical neurons (Fig. 6A, middle panel) . This high colocalization was similar to that (93%) of proBDNF with HAP1 (Fig. 6A, top panel) and 85% of proBDNF with sortilin (Fig. 6A, bottom panel) . The result suggested that proBDNF, HAP1, and sortilin could form a complex in cortical neurons. To further confirm this idea, we performed Co-IP using co-transfected HEK293 cell lysate. We found that proBDNF and sortilin were present in the sample immunoprecipitated with HAP1 antibody (Fig. 6B, d and e) . Alternatively, we also found that HAP1 and sortilin were present in the samples immunoprecipitated with proBDNF antibody (Fig. 6B, b and f) . Additionally, we found that HAP1 and proBDNF were present in the samples immunoprecipitated with sortilin antibody (Fig. 6B a and c) . No specific band was found when non-specific immunoglobulin was used for co-IP. Thus, we conclude that proBDNF, sortilin, and HAP1 form a complex in neurons.
proBDNF degradation was prevented by coexpression of sortilin in transfected HEK293 cells. Sortilin was found to improve proBDNF trafficking in HAP -/-neurons ( Fig. 4B ) and also formed a complex with proBDNF and HAP1 (Fig.  6B) , suggesting that the intracellular sortilin may have an important function in proBDNF trafficking and stabilization. To demonstrate the role of sortilin in the formation of proBDNF/HAP1 complex, we analysed the efficiency of proBDNF/HAP1 immunoprecipitation in the presence or absence of sortilin by Co-IP. We found that proBDNF was less immunoprecipitated by HAP1 antibody in the absence of sortilin, showing a significant difference (p<0.05) (Fig. 7A) . This data suggests that sortilin may be involved in proBDNF stabilization. To further test this hypothesis, we co-transfected HEK 293 cells with proBDNF and HAP1 with or without sortilin in the presence or absence of cycloheximide (CHX), a chemical that blocks protein synthesis.
Anti-GFP, antiproBDNF and anti-BDNF antibodies were used for specific validation. We found that the protein level of proBDNF was positively correlated with the increased amount of sortilin plasmids. (Fig. 7B,  top panel) . All β-actin and HAP1 for internal controls or loading variations were consistent to each other, ruling out the possibility of a loading variation. The results generated by blotting with anti-GFP were similar to that probed with antiproBDNF and anti-mature BDNF, suggesting that the detection of proBDNF and BDNF was specific.
To further examine if proBDNF was more stable in the presence of HAP1 and sortilin, we performed a time course for Western blot to measure the degradation of synthesised proBDNF in HEK293 cells cotransfected with all three plasmids and treated with CHX. We found that the level of proBDNF protein was much less in the absence of sortilin plasmid after CHX treatment for 2 and 4 hours, showing a significant difference (p<0.05) between the cells with and without sortilin (Fig. 7C) . The decrease of proBDNF was decelerated at 12 hours but continued during 24 hours after CHX treatment (Fig. 7C) . The consistent β-actin level ruled out the loading variation, but suggested that the proBDNF complex lacking sortilin might be easily exposed to proteasome and degraded.
The ProBDNF-HAP1-sortilin complex favours furin cleavage and production of mature BDNF. We showed that the level of mature BDNF increased in the cell lysate co-transfected with proBDNF, HAP1A and sortilin, compared to the cell lysate without sortilin (Fig. 7B) . To investigate whether the complex takes advantage of furin cleavage to release mature BDNF, we examined furin processing of proBDNF in the presence of HAP1 and sortilin or proBDNF alone in vitro (Fig. 8) . We performed Western blotting with sheep anti-proBDNF and sheep anti-BDNF antibodies to detect the ratio of BDNF/proBDNF. We found that the ratio was significantly higher in the digestion mixture containing proBDNF-YFP, HAP1A-CFP and sortilin-Myc (lane 2), compared with the mixture containing proBDNF alone (lane 1), suggesting that the complex of proBDNF/HAP1/sortilin might facilitate furin cleavage to release mature BDNF in vivo.
DISCUSSION
BDNF is synthesized as a precursor (proBDNF), which is anterogradely transported via axon to presynaptic nerve terminals for release (60, 61) . However, the mechanism of how proBDNF is anterogradely transported remains unclear due to a highly regulated and complex process. Our previous study revealed that HAP1 interacts with the prodomain of BDNF, which was possibly involved in regulating proBDNF axonal trafficking and secretion (54) . In this study, we sought to extend our understanding of proBDNF trafficking and its molecular insights. Our data demonstrated that 1) proBDNF associated with both HAP1 and sortilin, and formed a complex with these two molecules during its trafficking; 2) HAP1 and sortilin increased proBDNF targeting to dendrites and axonal organelles; 3) sortilin stabilized intracellular proBDNF protein and may facilitate furin cleavage to release mature BDNF.
HAP1 and sortilin form a complex with proBDNF, which is important for proBDNF intracellular trafficking. The prodomain of BDNF is involved in intracellular transport of proBDNF towards both axonal nerve terminals and dendritic trees for the regulatory release of BDNF. The sorting of proBDNF to secretory pathway requires the interaction between the prodomain of BDNF and sortilin at the trans-Golgi network (36) . The importance of the prodomain in proBDNF trafficking is demonstrated by a polymorphism that replaces a valine by methionine at codon 66 in the prodomain (62) , which dramatically decreases the secretion of BDNF. In addition to these reports, we found that the prodomain could directly interact with HAP1. HAP1 knockout in neurons caused a defect in proBDNF transport in sciatic nerve in vivo and in dendrites in vitro (50) . We further mapped the binding sites between proBDNF and HAP1, showing that HAP1 aa 371-445 contains a key binding site for proBDNF. The flanking sequences may also play a role in the binding affinity because more proBDNF was pulled down in the presence of the flanking region (Fig. 3A) . It is possible that the broad region is required for high conformational changes in protein-protein interaction. The binding site of proBDNF to HAP1 was determined between aa 65-90 (Fig. 3B) . The V66M mutation in this region dramatically decreases dendritic targeting and the secretion of BDNF (3, 62) . The V66M mutation also causes a significant reduction in the binding affinity of the prodomain to sortilin (49) . It is likely that HAP1 acts as a bridge or adaptor linking proBDNF to motor protein such as p150 glued subunit of dynactin which facilitates anterograde axonal transport of proBDNF along the microtubule (63) . The V66M mutation might impair the connection leading to insufficient trafficking of proBDNF to dendrites and nerve terminals. An intense FRET signal from the prodomain/HAP1 and proBDNF/HAP1 but not from mature BDNF/HAP1 (Fig. 1B) suggests that the molecular mechanism of proBDNF trafficking is different from mature BDNF.
The interaction between proBDNF and sortilin has been reported (36) . Interestingly, we found that sortilin not only interacts with proBDNF but also with HAP1 (Fig. 6B) , suggesting that proBDNF forms a complex with both HAP1 and sortilin intracellularly. HAP1 is a cytoplasmic protein containing a number of binding protein partners. Our findings also show its interaction with sortilin. The colocalization between proBDNF, HAP1, and sortilin was seen not only in co-transfected PC12 cells but also in mouse cortical neurons ( Fig. 2A and Fig. 6A ). Our immunoprecipitation and co-localization data showed that proBDNF, HAP1 and Sortilin are always in the same Co-IP samples or subcellular vesicles, suggesting that the complex formation may be important for proBDNF functions. More interestingly, lack of HAP1 did not impact on secretogranin vesicle transport (Fig. 2B) , indicating that HAP1 specifically regulated proBDNF vesicle transport. In addition, loss of HAP1 does not down-regulate the proBDNF mRNA expression (Fig. 2C) , whereas Htt -/-does (50, 51, 64) , suggesting that HAP1 has a different mechanism in regulation of proBDNF trafficking. Based on the current studies, we suggest that proBDNF trafficking is likely governed by its binding proteins in neurons. HAP1 may participate with sortilin and other cofactors in regulating proBDNF axonal trafficking (30, 33) . The proBDNF / HAP1/sortilin complex may be required for proBDNF trafficking from Golgi to the nerve terminal. This hypothesis is confirmed by FRAP of HAP1 rescue studies, showing that reintroduction of HAP1 and sortilin cDNA into HAP1 -/-neurons improves the defective trafficking of proBDNF-YFP (Fig. 4A, 4B) . Given that the regulatory mechanism of proBDNF transport is a complex process, other cofactors in addition to HAP1 and sortilin may be recruited for efficient transport of proBDNF. It is reported that HAP1 interacts with the p150
Glued subunit of dynactin (63, 65) and the kinesin light chain (66) . p150 Glued and kinesin light chain are components of dynein motor (24, 27, 28) and kinesin motor (24, 25) , respectively. HAP1 has been reported to interact with p150
Glued (63) which mediates Golgi transport vesicles to MTs (29) . Indeed, our results have shown that proBDNF, HAP1 and MTs are highly co-localized (Fig. 5C ) and 96% of proBDNF and p150
Glued are co-localized in WT neurons (Fig. 5D  top panel) . In contrast, this co-localization was significantly decreased in HAP1 -/-neurons (Fig.  5D, bottom panel) , reflecting a defect of proBDNF trafficking without HAP1 in the complex. The V66M mutation may destabilize proBDNF/HAP1/sortilin complex, resulting in dissociation with other trafficking factors such as p150
Glued (23), 14-3-3 protein (67), HIP-14 (68), HIP1R (61) , carboxypeptidase E (69) and Htt (34, 45) .
Hence, impairment of the proBDNF/HAP1/sortilin complex formation may lead to inefficient transport of proBDNFcontaining vesicles and reduction of proBDNF secretion. Sortilin is engaged in Golgi-endosome transport (42) . Our data show that HAP1 interacts with sortilin (Fig. 6B) and colocalized with proBDNF in Golgi area (Fig. 5A) , suggesting that Golgi may be the first place where HAP1 and sortilin are recruited into the complex with proBDNF for its anterograde trafficking. Our results also demonstrate that HAP1 and proBDNF are co-localized with other intracellular organelles such as CD71 (endosome marker), Tau (microtubule marker) and neurites in WT cortical neurons ( Fig. 5B and C) . In contrast, lack of HAP1 leads to the retention of proBDNF in Golgi and a decreased colocalization of proBDNF with endosome marker CD71. Therefore, the Golgi region may provide sites for proBDNF, HAP1 and sortilin to form a functional motility complex. The ~95% co-localization among HAP1, proBDNF and endosomal marker CD71 suggests that Golgi to/from endosomal transport is a part of proBDNF trafficking process. Endosomes can sort and transport proteins from vesicles to trans-Golgi network or directly release the luminal vesicle from the cell via exosomes (70) before they reach lysosomes for degradation (71). It is known that p150
Glued is associated with sorting nexin 5 and 6 which are components of retromer subcomplexes mediating endosomes to Golgi transport (72) . In addition, sortilin through sorting nexin 1 or GGA sorting protein mediates endosome to/from Golgi transport (42, 73) . It is likely that the complex of proBDNF/HAP1/sortilin may be sorted back to trans-Golgi network via interacting with retromer proteins, preventing them from targeting lysosomes or proteasomes for degradation.
ProBDNF/HAP1/sortilin complex prevents proBDNF degradation and facilitates mature BDNF release by furin cleavage. We demonstrated that proBDNF forms a complex with HAP1 and sortilin, which is required not only for proBDNF axonal trafficking and sorting to the secretory pathway but for preventing proBDNF degradation. Our data showed that the exogenous expression of proBDNF was degraded in cotransfected HEK293 cells without the expression of sortilin (Fig. 7) . Indeed, this result was in agreement with the study that secreted sortilin forms a complex extracellularly with the secreted proBDNF in vitro, which reduces its degradation in the presence of plasmin (74) . In fact, we have found a sortilin dose-dependent preservation of proBDNF in the presence of protein synthesis inhibitor, and mature BDNF production is likely increased at higher doses of sortilin. We also found that sortilin prevented degradation of proBDNF and facilitated cleavage by furin (Fig.  8) , suggesting that the complex may be required for the intracellular stablization of proBDNF and for its proper processing to produce mature BDNF. Indeed, it is evident that the protein level of proBDNF is significantly lower in HAP1 -/-than in WT (Fig. 2C bottom) . As proBDNF and mature BDNF have differential functions, the regulation of proBDNF and mature BDNF production due to the complex stabilization may have biological significance during development and in neurological disorders. However, how the proBDNF/HAP1/sortilin/ complex modulates proBDNF processing in vivo needs further elucidation.
In conclusion, our findings provide new insights into dendritic and axonal targeting of proBDNF in cortical neurons. The interaction between proBDNF, HAP1 and sortilin may be the key to form the functional motility complex. Our results, for the first time, suggest that Golgi and endosomes may be involved in proBDNF trafficking. The impairment of formation of proBDNF/HAP1/sortilin complex in vivo leading to proBDNF degradation may underlie the reduction in BDNF secretion in human neurological disorders. ProBDNF-YFP lysate was used for incubation with GST-HAP1 1-350 fusion protein and proBDNFMyc lysate for incubation with all other GST-HAP1 fusion proteins in GST-pulldown assays. ProBDNF-YFP used for GST-HAP1 1-350 pulldown assay is indicated by an arrow (top), and blotted with rabbit anti-GFP antibody (α-GFP). ProBDNF-Myc used for all other GST-HAP1 pulldown assays is indicated by an arrow from pulled-down and input samples (bottom), which was blotted with mouse anti-Myc antibody (α-Myc). The proBDNF binding region is indicated between dashed lines. B: The proBDNF peptides competition assay. Five specific proBDNF peptides (proBDNF 44-60, proBDNF 55-74, proBDNF 65-80, proBDNF 75-90 and proBDNF 85-100) and one non-specific PSMA peptide used for competing proBDNF-YFP binding to GST-HAP1 153-599 in GST-pulldown assay are listed at the top. The positive band of proBDNF-YFP is shown in the input lane. The arrow indicates proBDNF-YFP either pulled-down by GST-HAP1 153-599 in the competition assay or input samples. On the right, the average inhibition of the proBDNF peptides on the interaction between proBDNF-YFP and GST-HAP1 153-599 from three individual experiments is indicated as % over the non-specific PSMA peptide which was calculated as 0% inhibition. -/-mouse cortical neurons were immunostained for proBDNF (red) and cis-Golgi (blue). A 3 × enlargement of the white square box showed in merged panels was present on the right. B: proBDNF and HAP1 are colocalized with CD71, a marker for endosome. Top panel: mouse cortical neurons were immunostained for proBDNF (red), endosome marker CD71 (green), HAP1 (blue). The merged image is shown in white. A snapshot of colocalization between CD71 and proBDNF or HAP1 is shown on the right. Bottom panel: HAP1 -/-mouse cortical neurons were immunostained for proBDNF (red), endosome marker, CD71 (green), with the merged image in yellow. A snapshot of colocalization between CD71 and proBDNF is present on the right. The quantitative colocalizations are represented as a mean ± SEM (n=5 neurons). Significant: p < 0.05. C: proBDNF and HAP1 are colocalized to microtubule. Primary cultured mouse cortical neurons were immunostained for proBDNF (red), HAP1 (green) and Tau (blue). A 6 × enlargement of the white square box showed in the merged panels is present in the lower left corner. D: proBDNF is colocalized with p150
FIGURE LEGENDS
Glued in cortical neuron. Top panel: primary cultured mouse cortical neurons were immunostained for proBDNF (red), p150
Glued (green), DAPI (blue) and the merged image in yellow. A snapshot of colocalization is present on the right. Bottom panel: primary cultured HAP1 -/-mouse cortical neurons were immunostained for proBDNF (red), p150
Glued (green), DAPI (blue), with the merged image in yellow. A snapshot of colocalization is present on the right. The quantitative colocalizations are represented as a mean ± SEM (n=5 neurons). Significant: p < 0.05. 
